Docetaxel /m²

Phase 3Small molecule

Docetaxel /m² is one of 40 small molecule programs targeting Prostate Cancer (Adenocarcinoma). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate Cancer (adenocarcinoma)Recruiting

Prostate CancerActive, not recruiting

Prostate Cancer (adenocarcinoma)Phase 1

Recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Cabometyx

Bristol-Myers Squibb

Phase 3

12 3

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

10 4

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 5

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 6

Docetaxel /m²

AstraZeneca

Phase 3

2 7

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 8

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 9

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Prostate Cancer (adenocarcinoma)

NCT07316686

Q2 2027

Phase 3Active, not recruiting

Prostate Cancer

NCT03574571

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03574571·732 enrolled

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Withdrawn·PPeng Wang, MD PhD·Phase 1/2·NCT03343977

Small Cell Lung Cancer1 trial

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01750281·212 enrolled

Melanoma1 trial

A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Completed·YYonsei University·Phase 2·NCT02223884·30 enrolled

Prostate Cancer (Adenocarcinoma)1 trial

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Recruiting·IInstituto do Cancer do Estado de São Paulo·Phase 1·NCT07316686·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Docetaxel /m². U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetaxel /m² compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetaxel /m². EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Docetaxel /m²

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Prostate Cancer2 trials

Small Cell Lung Cancer1 trial

Melanoma1 trial

Prostate Cancer (Adenocarcinoma)1 trial

References

Drug Info

Quick Facts

Related News